PACAP (1-27), human, ovine, rat 产品活性：PACAP (1-27), human, ovine, rat (PACAP 1-27) 是 PACAP-38 的 N-末端片段，是一种有效的 PACAP 受体拮抗剂，对大鼠 PAC1，大鼠 VPAC1 和人 VPAC2 的 IC50 值分别为 3 nM，2 nM 和 5 nM。 产品来源： https://www.medchemexpress.cn/PACAP__1-27_,_human,_ovine,_rat.html 研究领域：GPCR/G Protein 作用靶点：PACAP Receptor In Vitro: Radioligand receptor binding assays with I-monoiodinated PACAP (1-27), human, ovine, rat confirms the presence of PAC -receptors on AR4-2J cells, since PACAP (1-27), human, ovine, rat and PACAP(1–38) equipotently displaces radioligand binding with a Kd of 1-2 nM, whereas vasoactive intestinal peptide (VIP) is 1000-fold less potent. PACAP (1-27), human, ovine, rat exhibits a distinct and much higher susceptibility to VIP-amino acid substitutions. PACAP (1-27), human, ovine, rat has potency and binding affinity to stimulate IP3 and cAMP formation in AR4-2J cells. In Vivo: The inhibitory effect of pituitary adenylate cyclase activating polypeptide (PACAP (1-27), human, ovine, rat) on the increase in total pulmonary resistance (RL) causes either by allergen or histamine in anaesthetized, ventilated guinea-pigs is studied. PACAP (1-27), human, ovine, rat given via i.v. infusion (0.045-4.5 nmol/kg/min) dose-dependently reduces the increase in RL caused by inhaled ovalbumin and histamine. At the highest dose, PACAP (1-27), human, ovine, rat prevented the increase in RL caused by ovalbumin and histamine completely. Infusion of PACAP (1-27), human, ovine, rat and the β2-adrenoceptor agonist, salbutamol (0.045-4.5 nmol/kg/min) inhibit the increase in RL similarly, but salbutamol increases the heart rate more than PACAP (1-27), human, ovine, rat. 相关产品：Bioactive Compound Library Plus | Peptide Library | PACAP (1-38), human, ovine, rat | PA-8 | PACAP (6-38), human, ovine, rat TFA | PAC1R antagonist 1 | PA-9 | PACAP (1-27), human, ovine, rat TFA | PACAP (1-38), amide, Biotin-labeled | PACAP-38 (16-38), human, mouse, rat | [Arg-15,20,21,Leu17]-PACAP-Gly-Lys-Arg-NH2 | PACAP-Related Peptide (PRP), human 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。